Skip to main content
. 2006 Feb 11;332(7537):325–329. doi: 10.1136/bmj.38733.466748.7C

Table 3.

Bleeding complications during study treatment of older (≥60 years) medical patients randomised to the anticoagulant fondaparinux or placebo

Bleeding complication Fondaparinux group (n=425) Placebo group (n=414)
Major bleeding:
Fatal 0 0
Requiring surgical intervention 0 0
In a critical location 0 0
Overt bleeding plus a decrease in haemoglobin concentration ≥20 g/L (<48 hours) or transfusion of ≥2 units 1 1
Total No (%) 1 (0.2) 1 (0.2)
Minor bleeding 11 (2.6) 4 (1.0)